| Name | Title | Contact Details |
|---|
Accelerating progress and time to market of biopharmaceuticals with our integrated CDMO and Testing Service Platform. Global HQ in Philadelphia, PA.
Thorne Group Inc is a Youngwood, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Paradigm Capital Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ovos natural health is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.